<DOC>
	<DOC>NCT02262780</DOC>
	<brief_summary>Group 1: To investigate safety, tolerability and pharmacokinetics of Telmisartan + HCTZ (T40/H12.5 and T80/H12.5) Group 2: To investigate safety, tolerability and pharmacokinetics of Telmisartan + HCTZ (T80/H12.5 x 7 days)</brief_summary>
	<brief_title>Safety, Tolerability and Pharmacokinetics of Single Rising and Multiple Oral Doses of Telmisartan / Hydrochlorothiazide (HCTZ) in Healthy Male Volunteers</brief_title>
	<detailed_description />
	<mesh_term>Telmisartan</mesh_term>
	<mesh_term>Hydrochlorothiazide</mesh_term>
	<criteria>Healthy males according to the following criteria: No finding deviating of clinical relevance and no evidence of a clinically relevant concomitant disease based upon a complete medical history, including the physical examination, vital signs (blood pressure (BP), pulse rate (PR), body temperature), 12lead ECG, clinical laboratory tests Age ≥20 and Age ≤35 years Body Mass Index (BMI) ≥17.6 and BMI ≤26.4 kg/m2 Signed and dated written informed consent prior to admission to the study in accordance with "Good Clinical Practice (GCP)" Gastrointestinal, hepatic, renal, respiratory, cardiovascular, metabolic, immunological or hormonal disorders Diseases of the central nervous system (such as epilepsy) or psychiatric disorders or neurological disorders Chronic or relevant acute infections Any laboratory value outside the reference range that is of clinical relevance Positive result for hepatitis B surface (HBs) antigen, anti hepatitis C virus (HCV) antibodies, Syphilitic test or HIV test Surgery of gastrointestinal tract (except appendectomy) History of relevant orthostatic hypotension (mean standing SBP varies by ≥ 20 mmHg from mean supine systolic blood pressure (SBP) and/or mean standing diastolic blood pressure (DBP) varies by ≥ 10 mmHg from mean supine DBP), fainting spells or blackouts. History of hepatic dysfunction (e.g. biliary cirrhosis, cholestasis) History of serious renal dysfunction History of bilateral renal artery stenosis or renal artery stenosis in a solitary kidney History of cerebrovascular disorder History of hyperkalemia Known hypersensitivity to any component of the formulation; known hypersensitivity to any other angiotensin II receptor antagonist; known hypersensitivity to sulfonamides or sulphonamidederived drugs (e.g. thiazides) History of impaired glucose tolerance History of hypokalemia History of hyperuricemia Salt restriction therapy Intake of drugs with a long halflife (&gt; 24 hours) within at least one month or less than 10 halflives of the respective drug prior to administration or during the trial Use of drugs which might reasonably influence the results of the trial based on the knowledge at the time of protocol preparation within 7 days prior to administration or during the trial Participation in another trial with an investigational drug within four months or 6 halflives of the investigational drug, whichever is longer, prior to administration or during the trial Smoker (more than 20 cigarettes /day) Alcohol abuse Drug abuse Blood donation (more than 100 mL within four weeks prior to administration or during the trial) Excessive physical activities (within seven days prior to administration) Intake of alcohol within two days prior to administration Inability to comply with dietary regimen of study centre Inability to comply with smoking cessation during hospitalization</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>35 Years</maximum_age>
	<verification_date>October 2014</verification_date>
</DOC>